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Laparoscopic Staging of
Malignant Disease
John H. Payne, Jr., MD, FA. C. S.
The earliest applications of laparoscopy were for diagnostic proce
dures. The goal was to make a diagnosis while sparing the patient
a major, and often futile, operation. However, the view was limited
and it was not possible to palpate organs or masses. The recent
development ofadvanced laparoscopic techniques and ultrasound
have improved our view and restored our sense of touch “. These
innovations bring the goal of minimally invasive diagnosis and
staging closer to reality. This paper reviews the current literature on
the laparoscopic staging of cancer with an emphasis on patient
selection, diagnostic accuracy, and the reduction in morbidity
which can be achieved.
Introduction
Over the last decade therapeutic laparoscopy has undergone an
explosive growth. Early success with laparoscopic cholecystectomy
has encouraged innovative surgeons to apply minimal access tech
niques to a growing list of procedures. It has also led us to return to
our historic roots. Before the advent of the CCD camera and the
increasingly sophisticated instruments, laparoscopy was used pri
marily for diagnosis. Inspection of the viscera and biopsy of abnor
mal tissue were the primary goals.
Diagnostic laparoscopy was introduced by Ott, a Russian gyne
cologist, in 19031 and by Kelling.2A few years later, the concept of
the pneumoperitioneum was formulated and the word “laparoscopy”
coined by Jacobeaus.3He also described the diagnosis of cirrhosis,
metastatic disease, and tuberculous peritonitis. As part of the world
wide effort to “stage” malignant diseases. Benedict was among the
first to discover that gastric, colonic, and ovarian malignancies
could produce ascites.4
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The development of a standardized system of staging malignant
disease paralleled the progress in diagnostic laparoscopy. The early
work of Pierre Denoit5 in the 1940s was formalized in the 1980s
when the International Union Against Cancer (UICC) and the
American Joint Committee on Cancer (AJCC) adopted the TNM
(Tumor, Nodes, Metastases) system.6
Diagnostic laparoscopy can be complementary to other modali
ties and detect lesions beyond the resolution of other imaging
methods. Its use to improve the staging and to allow the palliative
treatment of advanced disease is becoming even more common.
Patient Selection and Techniques
Since general anesthesia and a pneumoperitoneum are generally
required to optimize diagnostic laparoscopy, it is important to
thoroughly evaluate the patient’s cardiac and pulmonary system. In
elderly patients with compromised function, monitoring end-tidal
CO2will be necessary to prevent respiratory acidosis. The decreased
venous return which a pneumoperitoneum and the reverse
Trendelenberg position can produce makes the accurate assessment
of intravascular volume critical. Sequential compression stockings,
a Foley catheter, and a beanbag to support the patient during frequent
position changes are even more important in this high-risk group.
Alternate access techniques may be necessary if the patient has
had prior surgery or if there are masses or ascites present. The first
step is a thorough inspection of the entire peritoneal cavity. This may
detect small serosal implants which have eluded preoperative imag
ing. Relatively advanced laparoscopic skills are required. The
surgeon must be comfortable entering the lesser sac or the
retroperitoneum and obtaining tissue by biopsy or nodal dissection.
Intraoperative ultrasound may compensate for the inability to pal
pate structures during laparoscopy. Collaboration with a trained
ultrasonographer will make this a much more rewarding effort.
Changing the patient’s position will facilitate these procedures.
Staging Gastrointestinal Malignancies
There is ample evidence to suggest that the sensitivity and
specificity ofdiagnostic laparoscopy can rival, and perhaps, surpass
that of the usual preoperative imaging methods.7 When coupled
with intraoperative ultrasound, this advantage may even be greater.
Since neither chemo nor radiation therapy can provide significant
long-term survival for patients with extensive metastatic disease,
avoiding unnecessary open explorations and permitting less morbid
palliative procedures are important goals in the care of cancer
patients. However, the procedure is not without risk. It should only
be used in those cases where the potential diagnostic gain outweighs
any risk.
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Tumors of the Esophagus and Cardia
The current staging of these tumors is aimed at assessing the depth
of wall penetration, lymphatic spread, and systemic metastases.’21f
paraesophageal nodal disease is present, five-year survival for most
patients with esophageal carcinomas is unlikely. Early detection and
careful staging can minimize the frequency of futile resections while
identifying those who might benefit from aggressive treatment.
Only accurate tumor staging allows an adequate selection of appro
priate treatment and a correct assessment of the response to preop
erative therapy. Both endoscopic ultrasound and diagnostic
laparoscopy can contribute to this precision. Stein, et al’3 recently
reported a prospective study of 127 patients with no evidence of
metastatic disease referred for surgery or multimodal therapy.
Diagnostic laparoscopy with peritoneal lavage was performed in
each case. Because of technical problems with the probe, a complete
laparoscopic ultrasound examination was completed in only 88 of
the 127 patients. Forty-four relevant new findings were noted in 31
(24.4%) patients. Sixteen unsuspected liver metastases were found.
Fourteen of these were only found by laparoscopic ultrasound. The
sensitivity and specificity of laparoscopic ultrasound, percutaneous
ultrasound, and CT in evaluating celiac axis lymph nodes are shown
in Table 1.
Tumors of the Stomach
Although declining in incidence, gastric cancer remains a com
mon problem. Since most patients present with advanced disease, it
is still a major cause of cancer deaths. Resections for “cure” are
undertaken in less than 60%. At celiotomy, more than 25% will be
found to have been understaged by preoperative imaging.14 Since
standard adjuvant chemotherapy has done little to improve survival,
there is a growing interest in neo-adjuvant (treatment given prior to
surgery) protocols for these patients. For this approach to be suc
cessful, the patients must be accurately staged prior to their treat
ment. Diagnostic laparoscopy might be very useful for those with
apparently resectable disease.
In a recent series from Spain,15 76 patients with presumably
resectable cancers underwent diagnostic laparoscopy with intraop
erative laparoscopic ultrasound. Thereafter, twenty-nine (40.8%)
were found to be unresectable. The main reasons were peritoneal
metastases in 16, malignant ascites in 15, liver metastases in 12,
Krukenberg tumor in 2, and retroperitoneal fixation in 8. The other
42 patients were judged resectable. Only one of those was found to
be unresectable at celiotomy. Consequently, the diagnostic accu
racy of laparoscopy in determining resectability was 98.6 (70 of
71 patients). The sensitivity and specificity as confirmed by histol
ogy or celiotomy are shown in Table 2.
Results such as these have led to a wider application of diagnostic
laparoscopy to select patients more precisely for neoadjuvant therapy
and “curative” resection of gastric cancer. IS
Pancreatobiliary Cancer
Primary pancreatobiliary carcinoma is an ideal opportunity for
diagnostic laparoscopy. Despite the continuous development of
noninvasive imaging techniques, a large number are found to have
unsuspected metastatic disease at the time of exploration.’7Lavage
studies indicate that as many as 40% of patients with pancreatic
carcinoma already have diffuse peritoneal disease at the time of
presentation.’8Early detection of disseminated disease may avoid
unnecessary exploration in nearly a third of the patients sent for
surgery’92’and permit laparoscopic anlor endoscopic palliation.
Visual laparoscopy alone is inadequate to thoroughly evaluate the
pancreas or the biliary tract for evidence of locally unresectable or
distant disease. The addition of contact ultrasound has proven its
worth in open surgery.22The addition ofbiopsy guides to laparoscopic
ultrasound probes will facilitate sampling from the pancreas and the
retroperitoneum.
Pietrabissa, et al23 recently published their experience with 25
patients with suspected pancreatic cancer referred for surgery.
Preoperative staging to select those suitable for surgical referral was
accomplished with ultrasound; dynamic, contrast enhanced CT;
selective visceral angiography; and ERCP. Ascites or peritoneal
washings were sent for cytology at the beginning of each case.
Visual inspection of the peritoneum and liver followed. Attention
was then turned to the ligament of Treitz and the base of the
mesentery. Laparoscopic access to the lesser sac permitted direct
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Table 1. —Thesensitivityandspecificityof ultrasoundand Ctinevaluating
nodes in the celiac plexis. Stein, 19971
Sensitivity Specificity
(“True Positive”) (“True Negative”)
Laparoscopic Ultrasound 67% 92%
Percutaneous Ultrasound 35% 78%




(“True Positive”) (“True Negative”)
Serosal infiltration 77% 100%
Lymph node metastases 62.5% 100%
Livermetastases 100% 100%
Peritoneal metastases 89% 100%
Retmperitoneal infiltration 57% 100%
Ascltes 100% 100%
Table 3.—Laparoscopicstaging of pancreatic cancer. Pietrabissa, 1996
Standardlmaging Findingsatt.aparoscopy SurgicalOutcome
25 suspected 9 unresectable 3 pancreatectomies
pancreatic with vascular resection
carcinomas- 3 with locally advanced
believed to be disease and/or portal
resectable vein encasement
10 standard pancreatic
2 change of diagnosis reseclions
9 confined tumors 1 exploration alone
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ultrasonic scanning of the pancreas. The 
Iaparoscopic ultrasound, preferably with color 
Doppler, was very sensitive at detecting vascu-
lar invasion behind the head of the pancreas. For 
those judged resectable, definitive pancreatic 
resection was scheduled for 3-4 days after the 
staging procedure. The impact of laparoscopic 
inspection and ultrasound staging on surgical 
strategy in this series of 25 patients is shown in 
Table 3. 
From December 1992 to August 1994, 115 
patients seen at the Memorial Sloan-Kettering 
Cancer Center in New York with radiologically 
resectable peri pancreatic tumors underwent ex-
tensive laparoscopy before a planned curative 
resection. In this series Brennan, et aJ24 exam-
ined the peritoneal cavity, liver, lesser sac, porta 
hepatis, duodenum, transverse mesocolon, and 
celiac and portal vessels. A complete examina-
tion was possible in 108 of the 115 patients. 
Sixty-seven were considered to have resectable 
disease, and 61 resections were performed (91% 
accurate). Laparoscopy failed to detect hepatic 
metastases in 5 patients and portal venous en-
casement in 1 patient. Laparoscopic ultrasound 
was not routinely used. In two of the patients 
believed to be resectable after standard 
laparoscopy, the addition of laparoscopic ultra-
sonography detected hepatic metastases. The 
authors acknowledge that more regular use of 
Iaparoscopic ultrasound might have increased 
the accuracy to nearly 100%. Forty-one patients 
in this series were found to be unresectable at 
laparoscopy and were spared open exploration. 
In a series of patients from the same institution 
undergoing open exploration from 1993 - 1992, 
35% were found to be resectable. With the 
advent oflaparoscopic staging in the later series, 
the rate of resection was increased to 76% (p < 
0.00001) 
Staging Japaroscopy for presumed pancreatic 
malignancies should be confined to those cases 
where other, less-invasive modalities are nega-
tive or inconclusive. Used in this manner it can 
avoid unnecessary celiotomy in up to 42%. 
Colorectal Cancer 
Currently, there is no absolute indication for 
diagnostic Iaparoscopy in the evaluation of 
colorectal malignancies. However, when com-
bined with Japaroscopic ultrasound, the approach 
may compensate for the Joss of palpation and 
permit a more thorough evaluation of the liver. 
Using laparoscopy as a means to a "second-
look" may also play a greater role in the future. 
Nearly one half of all colorectal carcinomas will 
recur and most of those will do so within two 
years.25 Combining CEA levels and scanning, CT, diagnostic
laparoscopy, and intraoperative ultrasound those patients with an
early, potentially resectable, recurrence may be more rapidly and
successfully treated.
Prostatic and Ovarian Cancer
Early enthusiasm for laparoscopic staging of prostate cancer has
not been supported by clinical trials. Consequently, it is seldom
performed.
Laparoscopy can be helpful in staging GYN malignancies by
providing periaortic node samples and facilitating “second look”
operations. However, because the findings seldom materially affect
the need for or extent of surgery, it is not frequently employed.
Diagnosis and Staging of Abdominal Lymphomas
With the exception of Hodgkin’s Disease, the advent of high-
quality imaging techniques has reduced the need for surgical staging
of abdominal lymphomas. Although peripheral nodes may show the
presence of lymphoma, abdominal exploration is still recommended
for more than 85% ofHodgkin’s patients.2620-25% will be upstaged
(more widespread disease) after abdominal exploration.27Biopsy of
the liver and periaortic nodes and splenectomy can be accomplished
with yields similar to open surgery with less operative morbidity.
Whole node excision or wedge biopsy is used to prevent crush
artifact. Advanced laparoscopic skills are essential to a thorough
staging procedure.
Conclusion
Diagnostic laparoscopy utilizing ultrasonography can provide a
major advantage in the accurate staging of intraabdominal malig
nancies. As neoadjuvant protocols are developed for some tumors,
such precise staging will be critical to optimizing treatment choices
and monitoring treatment response. Further clinical trials are neces
sary to determine whether the trauma-induced immunosuppression
seen after celiotomy will be mitigated by a laparoscopic approach.
The issue ofport site recurrence has reduced the early enthusiasm for
laparoscopic colectomies. A similar concern must be expressed
about the use of laparoscopy for staging malignancies. Careful
attention to technique and surveillance will be critical to character
izing and minimizing this threat.
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